Hospira, Inc. recalled 15,750 vials of Sodium Bicarbonate Injection on August 4, 2025. The recall stems from a lack of assurance of sterility. Consumers and healthcare providers must stop using the product immediately.
Lack of Assurance of Sterility.
Consumers and healthcare providers should stop using this product immediately. Contact PFIZER INC or your healthcare provider for guidance. Notification method: Letter
The recalled product is Sodium Bicarbonate Injection, USP, 50mEq/50 mL, with Lot #: LH2671 and an expiration date of November 30, 2026. The product was distributed nationwide in the U.S.
The recall is due to a lack of assurance of sterility, which poses a high risk of contamination. This can lead to serious health issues for patients receiving the injection.
No specific incidents have been reported related to this recall. However, the potential for serious health risks remains.
Stop using the product immediately. Contact Pfizer Inc. or your healthcare provider for guidance on next steps.
For further information, consumers can visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0591-2025.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.